Abstract
The use of immunomodulators represented by thalidomide and its derivatives in the treatment of multiple myeloma (MM) has made a breakthrough. Cereblon has been identified as a direct target for immunomodulators and plays a significant role in antiproliferation, proapoptotic effects, antiangiogenic activities, enhancement of the activity of T cells and NK cells and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells. In recent years, majority of the MM patients treated with immunomodulators develop drug resistance. Both upstream and downstream factor expression of cereblon and epigenetic modification may be related to immunomodulatory drugs resistance in MM. This review discusses the mechanism of immunomodulatory drug resistance in MM. Key words: Multiple myeloma; Immunomodulatory drugs; Cereblon; Drug resistance
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.